Hydrochloric Acid

Hydrochloric Acid

SCHEMBL614210

NC(=O)C[n+]1ccccc1.[Cl-]

nearest known ligand 0.48

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

ACHEBDKRB2CHRM1CHRM2CHRM3CHRNA1CHRNB1CHRNDCHRNECHRNGGUCY1A1GUCY1A2GUCY1B1GUCY1B2NAMPTPTAFRSLC10A2SLC6A2SLC6A3TACR1dacAdacBdacCftsImrcAmrcBmrdA

The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
ACHE known ✓ P22303 2/20 0.41
KMT2A Q03164 3/20 0.48
CYP2C9 P11712 1/20 0.45
HSP90AA1 P07900 3/20 0.44
PABPC1 P11940 1/20 0.41
KDM4E B2RXH2 1/20 0.41
ALDH1A1 P00352 3/20 0.41
MAPK1 P28482 2/20 0.41
L3MBTL1 Q9Y468 2/20 0.41
MAPT P10636 2/20 0.41
POLB P06746 2/20 0.41
MEN1 O00255 1/20 0.41
RAB9A P51151 1/20 0.41
LMNA P02545 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5562270 0.97 KMT2A (0.50) KMT2ACYP2C9HSP90AA1PABPC1KDM4E
Hydrazine SCHEMBL9553603 0.80 KMT2A (0.48) KMT2ACYP2C9HSP90AA1PABPC1KDM4E
Hydrochloric Acid SCHEMBL19031444 0.79 KMT2A (0.52) KMT2ACYP2C9HSP90AA1PABPC1KDM4E
Hydrochloric Acid SCHEMBL344009 0.79 KMT2A (0.52) KMT2ACYP2C9HSP90AA1PABPC1KDM4E
Hydrochloric Acid SCHEMBL28662728 0.76 MEN1 (0.36) KMT2AKDM4EALDH1A1MEN1LMNA
SCHEMBL19037380 0.76 KMT2A (0.54) KMT2ACYP2C9HSP90AA1PABPC1KDM4E
SCHEMBL171879 0.76 KMT2A (0.54) KMT2ACYP2C9HSP90AA1PABPC1KDM4E
Hydrochloric Acid SCHEMBL420325 0.75 KMT2A (0.54) KMT2ACYP2C9HSP90AA1PABPC1KDM4E
Hydrochloric Acid SCHEMBL713375 0.75 HSP90AA1 (0.53) KMT2AHSP90AA1ALDH1A1MAPK1L3MBTL1
SCHEMBL15571095 0.74 KMT2A (0.52) KMT2ACYP2C9HSP90AA1PABPC1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 184 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-116875980-A Copper-reducing additive for HDI board and copper-reducing process 上海天承化学有限公司 2023-10-13 CN claimed
CN-106758498-B Water resistant oil resistant Cationic dispersed rosin size 南昌市龙然实业有限公司 2018-02-13 CN claimed
CN-106592335-B Cation colophony size for food wrapper 南昌市龙然实业有限公司 2018-02-13 CN claimed
CN-106758498-A Water resistant oil resistant Cationic dispersed rosin size 南昌市龙然实业有限公司 2017-05-31 CN claimed
CN-106592335-A Novel cation rosin sizing agent used for food packaging paper 南昌市龙然实业有限公司 2017-04-26 CN claimed
US-12404274-B2 Macrocycles as factor xia inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2025-09-02 US disclosed
CN-120129707-A Solid particles of silicone-functional copolymer, method for producing same, and cosmetic containing same 陶氏东丽株式会社 2025-06-10 CN disclosed
US-20240298520-A1 ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES UNIVERSAL DISPLAY CORPORATION (US) 2024-09-05 US disclosed
CN-116875980-A Copper-reducing additive for HDI board and copper-reducing process 上海天承化学有限公司 2023-10-13 CN disclosed
CN-107973809-B Macrocyclic compounds as factor XIA inhibitors 百时美施贵宝公司 2023-06-30 CN disclosed
US-20230058729-A1 MACROCYCLES AS FACTOR XIA INHIBITORS BRISTOL-MYERS SQUIBB COMPANY 2023-02-23 US disclosed
EP-3810596-B1 QUINOLINE DERIVATIVES USEFUL AS TYROSINE KINASE INHIBITORS RIGEL PHARMACEUTICALS INC (US) 2022-11-30 EP disclosed
EP-0540604-A1 SUBSTITUTED BICYCLIC BIS-ARYL COMPOUNDS EXHIBITING SELECTIVE LEUKOTRIENE B 4? ANTAGONIST ACTIVITY, THEIR PREPARATION AND USE IN PHARMACEUTICAL COMPOSITIONS Aventis Pharma S.A. (FR) 1993-05-12 EP disclosed
US-5155114-A Treating or preventing renal toxicity, nephrosis, nephritis FUJISAWA PHARMACEUTICAL COMPANY, LTD. (JP) 1992-10-13 US disclosed
WO-1992001675-A2 SUBSTITUTED BICYCLIC BIS-ARYL COMPOUNDS EXHIBITING SELECTIVE LEUKOTRIENE B4 ANTAGONIST ACTIVITY, THEIR PREPARATION AND USE IN PHARMACEUTICAL COMPOSITIONS RHONE-POULENC RORER S.A. (FR) 1992-02-06 WO disclosed
US-4985444-A Pyrazolopyridine compound and processes for preparation thereof FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1991-01-15 US disclosed
EP-0379979-A1 Pyrazolopyridine compounds and processes for preparation thereof FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1990-08-01 EP disclosed
US-4136033-A DIAZO COUPLERS SANDOZ LTD. (CH) 1979-01-23 US disclosed
US-4105665-A MONOMETHINE DYESTUFFS BAYER AKTIENGESELLSCHAFT (DE) 1978-08-08 US disclosed
US-4018796-A FIBERS BAYER AKTIENGESELLSCHAFT (DT) 1977-04-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12404274-B2 Macrocycles as factor xia inhibitors TFPI, TFPI2, F11 ACHE 3298/4885KMT2A 1111/4885CYP2C9 1012/4885
US-20230058729-A1 MACROCYCLES AS FACTOR XIA INHIBITORS TFPI, TFPI2, F11 ACHE 3298/4885KMT2A 1111/4885CYP2C9 1012/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.